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  | SUMMARY 
 
Intradialytic hypertension (IDH) is regarded as the paradoxical rise in blood pressure 
(BP) during chronic haemodialysis (HD). IDH increases morbidity and mortality. It is 
suggested that IDH may be due to subclinical fluid overload, but this has not been 
proven. 
 
A multicentre, cross-sectional study was conducted at four HD units in the Western 
Cape. Cases of IDH were defined as a rise of ≥10mmHg in systolic BP between pre-
dialysis and post-dialysis in at least four out of six consecutive dialysis sessions. One 
hundred and ninety participants were included in the final analysis. Fluid status using 
whole body bio-impedance measurements (Body composition monitor, Fresenius 
Medical Care), hourly data regarding the HD procedure, pharmacological data and 
demographic data were collected.  
 
There was a trend toward statistical significance regarding pre-dialysis fluid status 
when measured by whole body bio-impedance (mean overhydration (OH) pre-
dialysis was 2.6L [95% confidence interval (CI) 1.7–3.4] in the IDH group versus (vs.) 
1.8L [95% CI 1.4–2.1] in the control group; p=0.06). There was also a trend toward 
statistical significance in post-dialysis OH as measured by whole body bio-
impedance (mean post-dialysis OH was 0.79L [95% CI -0.04–1.62] in the IDH 
groups vs. -0.17L [95% CI 0.52–0.18] in the control group; p=0.06). Pre-dialysis 
percentage extracellular water (ECW) did not achieve a significant result as 
measured by whole body bio-impedance (mean pre-dialysis percentage ECW was 
12.3% [95% CI 8.3–16.3] vs. 9.6% [95% CI 7.8–11.5]; p=0.12) in IDH cases 
compared to controls. The post-dialysis results showed statistical significance with 
the IDH group’s mean percentage ECW decreasing to 3.5% (95% CI -1.4–8.5) 
compared to the control group’s mean percentage ECW of -1.4% post-dialysis (95% 
CI -3.7–0.8; p=0.04).  
 
There was no statistically significant difference regarding mean total ultrafiltration 
(UF) volume (2 274ml vs. 2 462ml; p=0.32) in the IDH vs. the control group.  
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There was no statistically significant difference regarding mean age (57.1 years vs. 
55.1 years; p=0.42), gender (males 53.7% vs. 59.5%; p=0.46), mean time-averaged 
sodium concentration (138.3mmol/L vs. 138.4mmol/L; p=0.72), mean dialysate 
calcium concentration (1.34mmol/L vs. 1.36mmol/L; p=0.45) or mode of dialysis 
(p=0.66) in the IDH group vs. the control group. 
 
There is a statistically significant trend towards a difference in hydration status 
between patients who develop IDH and patients with stable BP on dialysis. The 
researcher hypothesises that subclinical fluid overload may be primarily responsible 
in the development of IDH. 
 
 
 
 
 
Keywords: intradialytic hypertension, chronic haemodialysis, subclinical fluid 
overload, bio-impedance measurement 
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  1| INTRODUCTION 
  
1.1    Background 
 
The current guideline for target blood pressure (BP) in patients with chronic kidney 
disease (CKD) according to the Kidney Disease: Improving Global Outcomes 
(KDIGO, 2012b) guidelines is 130/80mmHg (non-diabetics) and 140/90mmHg 
(diabetics). 
 
Haemodynamic instability is a common complication in haemodialysis (HD); 
however, the focus is mostly on intradialytic hypotension rather than intradialytic 
hypertension (IDH), giving one a good idea of how the scales tip in terms of 
prevalence, awareness and general knowledge of IDH among the dialysis 
community. 
 
Currently there is no standard definition of IDH. Definitions vary widely. Chazot et al. 
(2010) define IDH as systolic BP rise of ≥10mmHg from start to finish of HD, rise in 
mean arterial pressure (MAP) during dialysis of 15mmHg or hypertension that 
appears resistant to ultrafiltration (UF) during or immediately after dialysis. Locatelli 
et al. (2010) suggest that the prevalence of IDH among HD patients varies between 
5% and 15%. Simply put, IDH is the paradoxical rise in BP during or immediately 
after HD.  
 
Inrig et al. (2007) and Inrig et al. (2009) showed that IDH increased the risk of 
hospitalisation and death, as reported in the Crit-Line Intradialytic Monitoring Benefit 
study and the United States Renal Data System HD study.  
 
The pathogenesis of IDH is unclear. A number of factors have been implicated and 
could be responsible, acting collectively or separately.  
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Factors that might have an impact include subclinical volume overload, as indicated 
by Agarwal et al. (2010), activation of the sympathetic system and the renin-
angiotensin-aldosterone system (RAAS), endothelial cell dysfunction, sodium gain 
during dialysis, use and route of administration of erythropoietin-stimulating agents 
and possible removal of antihypertensive agents during dialysis. 
 
The literature suggests that the management of IDH relies heavily on fluid dynamics 
and control of sodium in terms of diet as well as interdialytic management. 
Contradicting this statement, though, were the findings published by Van Buren et al. 
(2011); there was no difference in interdialytic weight gain (IDWG) between the IDH 
group and the control group in their study.  
 
This poses the following question: Is there a difference in hydration status between 
patients who develop IDH compared to patients with stable BP on dialysis? 
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1.2    Aim of the study 
 
The aim of this study was to determine whether patients with IDH were subclinically 
fluid overloaded. 
 
1.3    Objectives of the study 
 
1.3.1   Primary objective 
To compare overhydration (OH) (measured in L) between patients with IDH and the 
control group. 
 
1.3.2   Secondary objectives 
To determine the association/correlation between IDH and the following potential risk 
factors: 
 IDWG 
 Body mass index (BMI) 
 Time-averaged serum sodium concentration on HD 
 Dialysate calcium concentrations  
 Dialysis modality 
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 2 | LITERATURE REVIEW 
 
2.1 Introduction 
 
Chronic kidney disease is defined as a progressive, irreversible loss of renal function 
over a time period of more than three months (Levy et al., 2010). The KDIGO 
guidelines published in 2012 (KDIGO, 2012a) have developed a classification of 
CKD based on glomerular filtration rate (GFR) measured in ml/min/1.73m² (see 
Table 2.1).  
 
Table 2.1: Definition of CKD by GFR – stages 
 
Stage GFR description GFR  
(ml/min/1.73m²) 
G1 Normal or high ≥90 
G2 Mildly decreased 60–89 
G3a Mildly to moderately 
decreased 
45–59 
G3b Moderately to severely 
decreased 
30–44 
G4 Severely decreased 15–29 
G5 Kidney failure <15 
 
(Adapted from KDIGO, 2012a) 
 
The aim in terms of managing patients with CKD is predominantly to slow the rate of 
progression of renal damage. This can be achieved by diagnosis and treatment of 
reversible causes.  
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The focus would be on control of BP, glycaemia, dyslipidaemia, anaemia and 
hyperparathyroidism caused by renal damage, as well as prevention of symptoms, 
mainly those due to fluid overload and uraemia. These symptoms can present as 
early as Stage G3a (see Table 2.1). By reducing each of these markers, the rate of 
progression of renal damage and cardiovascular risk can be minimised (Levy et al., 
2010). 
 
The KDIGO guidelines (2012a) recommend that a patient with CKD be referred to a 
nephrologist and that a multidisciplinary renal team be prepared, both mentally and 
physically, for renal replacement therapy (RRT) when 
 there is an abrupt sustained decline in GFR; 
 a patient’s GFR <30ml/min/1.73m² (stages G4 and G5); 
 there is a consistent finding of significant albuminuria and/or urinary red cell 
casts; 
 a patient presents with a combination of CKD and hypertension irrespective of 
treatment with four or more antihypertensive agents; 
 a patient presents with persistent abnormalities of serum potassium; 
 there is recurrent or extensive nephrolithiasis (calculi in the kidneys); and 
 a patient has a hereditary kidney disease. 
 
Renal replacement therapy should be initiated when one or more of the following are 
present:  
 Symptoms or signs attributed to kidney failure. 
 Inability to control fluid volume status, resulting in OH and subsequent inability 
to control BP. 
 A progressive deterioration in nutritional status irrespective of dietary 
intervention. 
 Cognitive impairment due to uraemia.  
 
These symptoms often occur in the GFR range between 5ml/min/1.73m² and 
10ml/min/1.73m² in Stage G5 and are termed ‘end stage renal disease’ (ESRD) 
(KDIGO, 2012a). 
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Treatment options for RRT include renal transplantation, HD, peritoneal dialysis or 
conservative management. 
 
The number of ESRD patients receiving RRT in South Africa was 8559 at the end of 
2012, as shown in Table 2.2. This was reported in the first South African Renal 
Registry Annual Report 2012 (Davids et al., 2014). 
 
 
Table 2.2: Prevalence of RRT in 1994 and 2012 
 
 1994 2012 
Population in millions 40.4 52.3 
ESRD patients on treatment 2843 8559 
Treatment rate per million of 
population 
70 164 
 
(Adapted from Davids et al., 2014) 
 
The purpose of this IDH study was to evaluate patients on HD; therefore, the 
principles of the various types of HD will be discussed in this chapter. 
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2.2 Haemodialysis  
 
Haemodialysis is an extracorporeal blood purification treatment for patients with CKD 
in Stage G5. Blood is obtained through vascular access to the patient and pumped 
via a blood pump on the HD machine through an artificial kidney called a dialyser, as 
shown in Figure 2.1. 
 
 
 
Figure 2.1: HD circuit 
(Fresenius Medical Care Deutschland GmbH, 2012) 
 
The dialyser consists of hollow fibres called capillaries, with variable-sized pores in 
the walls of the capillaries, giving it semi-permeable characteristics. Certain solutes, 
depending on molecular weight, are allowed to move from the blood to the outside of 
the capillaries where the dialysate compartment is situated, as depicted in Figure 
2.2.  
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Figure 2.2: Movement of solutes according to molecular weight 
(Fresenius Medical Care Deutschland GmbH, 2007) 
 
A low electrolyte solution, dialysate, is pumped through the dialyser via a dialysate 
pump in the HD machine in a direction counter to that of the blood flow, as seen in 
Figure 2.3. 
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Figure 2.3: Structure of a dialyser 
(Fresenius Medical Care Deutschland GmbH, 2007) 
 
Basic principles in HD facilitating purification of the blood are diffusion, osmosis and 
UF. A concentration gradient between the high concentration of the blood compared 
to the low concentration of the dialysate permits diffusion of excess electrolytes to 
take place until equilibrium is reached. Small molecular weight electrolytes (e.g. 
urea, creatinine and potassium) are targeted by diffusion. UF is the removal of 
excess fluid from the blood. Osmosis and UF are facilitated by creating a hydrostatic 
pressure in the capillaries, namely transmembrane pressure.   
Modern HD machines have volumetric control systems whereby the actual UF rate 
(ml/hr) is measured directly by quantifying the volume of dialysate being pumped into 
and out of the dialyser (see Figure 2.3). The UF rate can be adjusted by altering the 
flow rates on the HD machine’s display (Levy et al., 2010). 
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2.3 Haemodiafiltration 
Continuous improvement of the efficiency of HD treatment modalities was 
necessitated by the unacceptably high morbidity and mortality rates among HD 
patients. Clearance of especially medium-sized and large molecules is not effectively 
facilitated by conventional HD (Maduell et al., 2013). As a result, haemodiafiltration 
(HDF) was developed to target improved clearance profiles for a broader range of 
small, medium-sized and large molecules.   
Basic principles in HDF facilitating purification of the blood are diffusion, osmosis, UF 
and the added benefit of convection. Convection is solute drag facilitated by the 
movement of fluid over the dialyser membrane, as depicted in Figure 2.4. 
 
 
Figure 2.4: Principles of HDF 
(Fresenius Medical Care Deutschland GmbH, 2007) 
 
The fluid to be utilised for convection in the dialyser does not originate from the 
patient but is rather manufactured by the dialysis machine online. This fluid is called 
‘substitution fluid’ and is a physiological fluid prepared online from dialysate. 
© Central University of Technology, Free State
 11 
During the dialysis treatment, the substitution fluid is administered via a volumetric 
pump in the dialysis machine into the extracorporeal circuit.  
 
Pre-dilution HDF occurs when the fluid is substituted before the dialyser, and post-
dilution HDF occurs when the fluid is substituted after the dialyser in the 
extracorporeal circuit. Post-dilution HDF is depicted in Figure 2.5. The exact amount 
of substituted fluid administered into the patient’s blood (not to exceed 30% of blood 
flow rate) is subsequently removed in the dialyser via the volumetric system of the 
machine. This causes a large fluid shift from the patient’s blood across the semi- 
permeable membrane of the dialyser into the dialysate compartment, dragging and 
clearing especially medium-sized and large molecules via convection. In combination 
with conventional diffusion and UF, the clearance for online HDF has been proven to 
be much more efficient than for HD (Canaud et al., 2000). 
 
 
Figure 2.5: Schematic diagram of post-dilution HDF 
(Fresenius Medical Care Deutschland GmbH, 2007) 
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Maduell et al. (2013) reported on a large study conducted in Spain, involving 906 
chronic HD patients. Four hundred and fifty patients continued with conventional HD, 
and 456 patients were switched to high-efficiency post-dilution HDF. The follow-up 
period was 36 months.  The primary outcome was all-cause mortality, and secondary 
outcomes included cardiovascular mortality, all-cause hospitalisation, treatment 
tolerability and laboratory data. The results were significant. Compared with patients 
who continued on conventional HD, those assigned to HDF had a 30% lower risk of 
all-cause mortality (p=0.01), a 33% lower risk of cardiovascular mortality (p=0.06) 
and a 55% lower risk of infection-related mortality (p=0.03), (Maduell et al., 2013). 
High-efficiency online HDF is now being recognised in the dialysis industry as an 
advanced HD treatment modality that improves patient outcomes. 
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2.4 Interdialytic weight gain and body mass index 
Interdialytic weight gain is calculated by measuring a patient’s weight/fluid gain 
between two HD sessions. Non-adherence to fluid restrictions results in excess 
weight gain between two dialysis sessions as the majority of HD patients have 
minimal residual renal function and are anuric. Patients who still produce large 
volumes of urine can adhere to less stringent fluid restrictions. Body weight biases 
the amount of IDWG and intradialytic weight loss (Denhaerynck et al., 2007). 
Compared with a lighter patient, a heavier patient will tolerate a larger percentage of 
body weight gained as fluid interdialytically. Denhaerynck et al. (2007) used a cut off 
value defined by Leggat et al. (1998) who defined a patient as non-adherent to fluid 
restrictions when the patient’s IDWG exceeded 5.7% of the patient’s dry weight 
(weight when patient is euvolaemic). The precise clinical relevance of this cut off 
value remains controversial. However, Leggat et al. (1998) further reported that 
patients who had greater IDWG than 5.7% of their dry weight had a 35% higher risk 
of death (p<0.001). The authors also commented that patients who had a good 
nutritional status with a BMI >23.0kg/m² (as published by the European Best Practice 
Guidelines, 2007) reflected a somewhat higher IDWG compared to patients who had 
a BMI <23.0kg/m².  
 
This is a contradictory statement, though, simply because a BMI >23.0kg/m² for 
dialysis patients is considered as being conducive to survival. A BMI >23.0kg/m² 
reflects a healthy lifestyle and good quality of life. 
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2.5 Bio-impedance monitoring 
Fluid overload is a common condition among patients on dialysis and one of the 
major causes of mortality, as explained in the previous section. Achieving optimal 
fluid balance (euvolaemia) remains a major clinical challenge in dialysis units, and 
assessment of fluid status based on subjective indicators, for example pedal 
oedema, pulmonary oedema, hypertension or cardiac dysfunction, has been a 
limiting factor. 
Levin et al. (1996) reported in their study published in the American Journal of 
Kidney Disease that improving the treatment of hypertension and correction of fluid 
balance has the potential to limit the development of left ventricular hypertrophy, thus 
increasing life expectancy. 
The need for alternative methods of accurate fluid assessment arose, and bio-
impedance spectroscopy was one of the techniques investigated. Moissl et al. (2006) 
reported that bio-impedance measurement might be an appropriate method for body 
fluid volume determination. It also proved to be accurate over a wide range of body 
compositions in different states of health and disease, which made it an ideal 
technique for CKD patients on dialysis. 
The Body composition monitor (BCM) from Fresenius Medical Care Deutschland 
GmbH was evaluated by Covic et al. (2009). The purpose of the study was to 
present epidemiological body composition data in dialysis patients to eventually 
optimise fluid balance and patient outcomes. The researchers recruited 150 
peritoneal dialysis patients to participate, and the results showed that 55% of the 
patients were overhydrated. The OH could not be predicted by their BP or body 
weight. In contrast, almost half of the OH patients (47%) had a systolic BP below 
140mmHg. The conclusion was that the BCM measurement provided essential 
information to identify patients at risk, thus supporting clinicians in optimising dialysis 
therapy and patient outcomes. 
 
The BCM used in the current study is based on a non-invasive and accurate method 
that is easy to apply, and results are obtained within minutes.  
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It employs bio-impedance spectroscopy techniques that measure at 50 different 
frequencies over a range from 5kHz to 1000kHz to determine the electrical 
resistances of the total body water (TBW) and the extracellular water (ECW). While a 
high-frequency current passes through the TBW, a low-frequency current cannot 
penetrate cell membranes and thus flows exclusively through the ECW. 
 
The BCM quantifies fluid status in terms of OH as well as the value for TBW that is 
used in dialysis quality measurements. It also assesses body composition in terms of 
lean tissue mass and adipose tissue mass. Based on the amount of OH (measured 
in L), the BCM can calculate accurately what the patient’s dry weight is. Dry weight 
can be described as the state during which the patient is in optimal fluid balance 
(euvolaemic). 
 
The BCM’s output parameters (see Table 2.3) have been validated against the gold 
standard reference methods in various studies involving more than 500 patients and 
healthy controls (Moissl et al., 2006; Wabel et al., 2009). 
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Table 2.3: BCM output parameters 
 
Key parameters Unit 
Overhydration (pre-/post-dialytic) L 
Lean tissue index  Kg/m² 
Fat tissue index Kg/m² 
Total body water  
(urea distribution volume) 
L 
Extracellular water L 
Intracellular water L 
ECW/ICW - 
Lean tissue mass Kg and % 
Fat mass Kg 
Adipose tissue mass Kg and % 
Body cell mass Kg 
 
(Adapted from BCM product folder, Fresenius Medical Care Deutschland GmbH, 
2007) 
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2.6   Blood pressure in haemodialysis 
 
Blood pressure is generated when the heart contracts against the resistance of the 
blood vessels. Typically hypertension results from an increase in systemic vascular 
resistance with normal cardiac output. However, with intermittently hypertensive 
patients (e.g. dialysis patients), increased cardiac output may be the only 
haemodynamic disturbance. Over time, cardiac output ‘normalises’ and systemic 
vascular resistance increases due to various factors to sustain the hypertension.  
 
The relationship between BP and clinical outcome in HD patients has always been a 
very complex issue; furthermore, hypertension is probably the most important 
complication of renal disease. However, in the majority of chronic HD patients, BP is 
supposed to decline when UF takes place during a dialysis session (excess fluid is 
removed over a time period). Unfortunately, there is a group of HD patients, 
presumed to be between 10% and 15% of the dialysis population, as reported by 
Agarwal et al. (2010), who’s BP increases rather than decreases during dialysis. This 
phenomenon is called IDH. Chazot et al. (2010) define it as systolic BP rises of 
≥10mmHg from start to finish of HD, rise in MAP during dialysis >15mmHg or 
hypertension that appears resistant to UF during or immediately after dialysis. 
 
Sustained hypertension is one of the main culprits causing left ventricular 
hypertrophy in chronic renal failure patients, increasing the risk of cardiovascular 
death greatly (Levy et al., 2010). As cited in the introduction, Inrig et al. (2007) 
showed that IDH increased the risk of hospitalisation and death, as reported in the 
Crit-Line Intradialytic Monitoring Benefit study.   
 
Analysis of 1748 incident HD patients in the United States Renal Data System study 
found that the adjusted hazard for death at two years for HD patients was 6% per 
10mmHg rise in systolic BP (Inrig et al., 2009). 
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Hypertension can be caused by various factors, and especially where IDH is 
concerned, the pathogenesis of it is still unclear. However, several studies have 
found that volume overload, be it clinical or subclinical, drives this process (Cirit et 
al., 1995; Gunal et al., 2002; Agarwal et al., 2010). These studies have also reported 
patients who presented with ‘malignant’ hypertension unresponsive to 
antihypertensive drugs but who became normotensive after an increasing rate of UF.  
 
A number of factors have been implicated in causing IDH and could be responsible 
as a collective or acting separately. Factors that might have an impact include 
subclinical volume overload, as indicated by Agarwal et al. (2010), activation of the 
sympathetic system and the RAAS, endothelial cell dysfunction, sodium gain during 
dialysis, use and route of administration of erythropoietin-stimulating agents and 
possible removal of antihypertensive agents during dialysis (Fourtounas, 2010; 
Locatelli et al., 2010). 
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2.7   Factors associated with intradialytic hypertension 
 
2.7.1 Subclinical volume overload 
Hypervolaemia (volume expansion) due to excessive intradialytic fluid gain is one of 
the most important factors that causes higher levels of BP in anuric patients with 
CKD. This has been known for quite some time and has resulted in the concept of 
‘dry weight’ in ESRD patients who are dependent on dialysis for volume control. Dry 
weight is defined as the lowest weight that a patient can tolerate without the 
development of symptoms or hypotension. According to the Kidney Disease 
Outcomes Quality Initiative guidelines published in 2005 (Levy et al., 2010), UF 
should be optimised in such a way that patients are normotensive and euvolaemic 
post-dialysis, in other words a BP of ±130/80mmHg and normal fluid balance (i.e. dry 
weight). Agarwal et al. (2010) showed very clearly in the post hoc analysis of the Dry 
Weight Reduction in Hypertensive Haemodialysis Patients trial conducted in 2010 
how UF and thus bringing patients closer to their dry weights could manipulate 
especially systolic BP and reported at baseline, intradialytic systolic and diastolic BP 
drop at a rate of 3%/h. The authors concluded that intradialytic BP changes 
appeared to be associated with change in dry weight among HD patients.   
 
Cirit et al. (1995) showed a similar result; the patients whom they investigated all had 
marked cardiac dilatation, but most did not present with signs of oedema associated 
with hypervolaemia. They were treated with repeated intense UF. After a variable 
time period, all the patients became normotensive without additional medication. The 
authors concluded that a paradoxical rise in BP with UF usually occurred in the 
presence of hypervolaemia but also stated that the explanation for this occurrence 
remained speculative.   
 
Gunal et al. (2002) suggested that the Frank–Starling law can explain the 
association of fluid overload and IDH. The authors reported patients who presented 
with low cardiac ejection fractions subsequent to serious deterioration in cardiac 
function, possibly resulting from chronic hypervolaemia and who were on the right 
down slope side of the curve (see Figure 2.6).  
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Following UF in the initial stage of dialysis, cardiac preload was moderately reduced 
and the ejection fraction was increased. Patients moved to the flat region of the 
curve, and the blood pressure reached a peak. Subsequently, with continuing UF, 
euvolaemia was obtained; patients moved to the left ascending slope side of the 
curve and became normotensive at the end of dialysis (see Figure 2.6). 
 
 
Figure 2.6: BP changes on dialysis explained by the Frank Starling curve 
(Adapted from Gunal et al., 2002) 
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2.7.2 Activation of the sympathetic and renin-angiotensin-aldosterone                   
systems 
Another option to be considered as the cause of IDH is the activation of the 
sympathetic system (catecholamine response) and/or activation of the RAAS due to 
UF-induced hypovolaemia causing excessive activation of these systems (possibly 
taking off too large a volume of fluid in too short a space of time, e.g. >500ml/hour. 
This can cause a sudden rise in systemic vascular resistance and an increase in BP. 
 
A completely opposite hypothesis to that proposed in the previous paragraph also 
exists. Chou et al. (2006) analysed the biochemical and hormonal status in 30 HD 
patients presenting with IDH and compared it to a control group of 30 patients 
without IDH. No significant differences were found between the two groups except 
for the MAP level, which was, as expected, higher in the IDH group. Contrary to the 
initial hypothesis, the plasma renin and norepinephrine increased in the control 
group but not in the IDH group. The absence of evidence of increased sympathetic 
activity in IDH patients remains to be confirmed by further studies utilising other 
methods exploring the sympathetic system. 
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2.7.3   Endothelial cell dysfunction 
Endothelial cells constitute the thin layer that lines the interior surface of blood and 
lymphatic vessels. The endothelial monolayer is able to transduce both mechanical 
and chemical signals into appropriate changes (vasodilation/vasoconstriction) in 
vascular smooth muscle tone under normal circumstances. Fluid volume changes 
during HD and physical and hormonal triggers result in the production of substances 
involved in BP control in endothelial cells.   
 
Three of the most important vasoactive substances are 1) nitric oxide, a powerful 
smooth muscle vasodilator and also an important signalling molecule; 2) asymmetric 
dimethylarginine, an endogenous inhibitor of nitric oxide synthesis; and 3) 
endothelin1, a vasoconstrictor. These substances have important effects on 
sympathetic activity, peripheral vasoconstriction and BP control. Inrig et al. (2011) 
reported that endothelial dysfunction (indirectly because of imbalances of nitric oxide 
and endothelin1) could cause considerable changes in BP during HD, including IDH. 
Fifty patients were studied, 25 without IDH (control group) and 25 with IDH.  
The results showed that endothelial cell function was markedly impaired in the IDH 
group.   
 
Chou et al. (2006) found differences in changes in nitric oxide and endothelin1 levels 
between control patients and individuals prone to IDH. At the end of dialysis, patients 
with IDH showed a significant increase in endothelin1 levels and a significant 
decrease in nitric oxide: endothelin1 ratio compared with control patients. This might 
give an indication that the interaction among nitric oxide, asymmetric 
dimethylarginine and endothelin1 has a significant role in controlling BP. Teng et al. 
(2014) reported a similar result as Chou et al. (2006). They studied 34 patients; 17 
control cases were age matched and sex matched to 17 IDH cases. Pre-dialysis 
there was no significant difference in endothelin1 levels or nitric oxide: endothelin1 
ratio between the two groups. However, Teng et al. (2014) found a significant 
increase in endothelin1 levels (p<0.05) post-dialysis in the IDH patients compared to 
the control group. There was also a significant decrease (p<0.05) in nitric oxide: 
endothelin1 ratio in the IDH group compared with control patients post-dialysis. 
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In support of the endothelial cell dysfunction hypothesis, Inrig et al. (2011) performed 
a 12-week pilot study on 25 HD patients in Dallas, Texas. Carvedilol (non-selective 
beta blocker/alpha-1 blocker indicated in the treatment of mild to severe congestive 
heart failure) has been shown to improve endothelial cell function; in vivo and in vitro 
studies also indicated that it blocked endothelin1 release. Each patient acted as his 
or her own control. The results of this study showed no significant change in 
endothelial progenitor cells, endothelin1 or asymmetric dimethylarginine levels. 
Interestingly, there was no change in pre-dialysis systolic BP over the 12 weeks, but 
the post-dialysis BP and, most importantly, the frequency of IDH decreased 
significantly on Carvedilol (p<0.001). Inrig et al. (2011) concluded that to improve 
endothelial cell function and achieve a subsequent lower incidence of IDH, 
Carvedilol should be prescribed to HD patients experiencing IDH as well as 
interdialytic hypertension. The authors suggested further investigation in the form of 
randomised controlled trials to confirm their findings. 
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2.7.4   Sodium gain during dialysis 
Fresenius Medical Care Deutschland GmbH (2012) compiled an extremely 
descriptive compendium, Sodium and UF profiles in dialysis: Structure, application 
and effect, in 2004, explaining the concept behind sodium and fluid shifts on a 
cellular level. 
 
Sodium is the most important osmotic agent in the extracellular volume (ECV). The 
sodium content defines the size of the ECV. The higher the sodium content, the 
higher the ECV, and vice versa. Take into consideration that the ECV correlates with 
the intracellular volume (ICV) and that the volume ratio of ECV to ICV is 
approximately 30:70. Also keep in mind that the ECV can be divided further into two 
compartments: the ICV (referred to subsequently when discussing sodium gain 
during HD) and the interstitial volume. Sodium concentrations in the ECV are 
142mmol/L–145mmol/L. In the ICV, sodium plays a much smaller role with a 
concentration of only 10mmol/L. 
 
Under normal physiological conditions, a state of osmotic balance is established by 
the distribution of the TBW between the compartments (as shown in Figure 2.7a). In 
case of a change in the osmotic balance in one of the compartments due to a 
change in the concentration of, for example, sodium, water crosses the cell 
membrane between the ICV and ECV until the osmotic balance between the ECV 
and ICV is restored again. Figure 2.7b shows, for instance, that when sodium 
concentration increases in the ECV, the fluid shifts from the ICV to the ECV; the ECV 
increases and the ICV decreases. When sodium concentration in the ECV 
decreases, fluid shifts from the ECV to the ICV, followed by an increase in the ICV 
and a decrease in the ECV (see Figure 2.7c). 
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ECV – Extracellular volume 
ICV – Intracellular volume 
IVV – Intravascular volume 
 
Figure 2.7: Simplified schematic presentation of the changes in the ratio  
         of sizes from the ICV to the ECV in changing sodium content  
                   in the ECV 
(Fresenius Medical Care Deutschland GmbH, 2004) 
 
Sodium promotes the fluid transport between the compartments. It is the driving 
force behind water transport and distribution between the ECV and ICV. 
 
According to the Kidney Disease Outcomes Quality Initiative guidelines published in 
2005, a positive sodium balance is the main mechanism of extracellular fluid 
overload and hypertension in dialysis patients (NKF KDOQI, 2005). The sodium 
balance becomes positive when dietary sodium intake exceeds sodium removal 
during dialysis, and a low-sodium diet should be advised for the majority of dialysis 
patients.  
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The sodium balance can also become positive when the patient’s body composition 
changes due to progressive fat and lean body mass loss without dry weight 
prescription adjustment.  
 
As noted by Locatelli et al. (2004), although a high sodium concentration in dialysate 
has been used to improve dialysis tolerance, it increases sodium diffusion and 
exposes the patient to a high intradialytic sodium load, which in turn can result in 
increased BP. Locatelli et al. (2010) elaborates on this further in a review article; if 
the sodium concentration in the dialysate is higher than the patient’s pre-dialysis 
plasma sodium concentration, sodium is given to the patient via diffusion so that the 
difference in concentrations equalises. In this case, the diffusive sodium transport to 
the patient counteracts the convective sodium removal that occurs as a result of UF. 
This phenomenon, however, causes insufficient net sodium removal, which can 
result in the development of refractory hypertension and IDH. 
 
In addition, dialysate with a high sodium concentration or manipulation of the 
dialysate via a high sodium profile (in relation to the patient’s plasma sodium) can 
trigger an intense sense of thirst, resulting in high water intake during the interdialytic 
period. Subsequently, this can trigger various complications (including cramps and 
hypotension) during the next dialysis session when the excess fluid needs to be 
removed with high UF rates. This can develop into a snowball effect, as elevated 
sodium concentration dialysate or 0.9% saline can be utilised to counteract the 
hypotension, again resulting in a sodium gain, often resulting in IDH, cardiac failure 
and pulmonary oedema. 
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2.7.5   Influence of dialysate calcium concentration  
The KDIGO guidelines published in 2009 suggested that target serum calcium levels 
for CKD patients on dialysis should be 2.2mmol/L–2.5mmol/L. The guidelines placed 
strong emphasis on avoiding hypercalcaemic episodes, for various reasons.  
 
Calcium concentrations vary in dialysis solutions from 1.25mmol/L to 1.75mmol/L, 
depending on the product and manufacturer. The dialysate calcium level tends to 
equilibrate with the ionised fraction of the serum calcium (which equates to 
approximately 60% of the body’s total calcium; the remaining 40% is bound to 
proteins and is therefore not dialysable).   
 
When prescribing the concentration of calcium-containing dialysate, besides the very 
important mineral and bone metabolism issues that might arise from subsequent 
abnormal serum calcium levels, one needs to consider the effect of dialysate calcium 
level on systemic BP. It has been shown that the use of a low-calcium dialysate 
(1.25mmol/L) is associated with a mild but significant decline in mean BP during 
dialysis (Sam et al., 2006). The decline in BP is mediated by a decrease in cardiac 
contractility. There is no change in systemic vascular resistance as initially 
speculated, though, as reported by Locatelli et al. (2004). It has been speculated that 
the opposite could be true: a high calcium dialysate (1.75mmol/L) can increase 
cardiac contractility, with a subsequent increase in mean BP while on dialysis. 
 
However, Chou et al. (2006) found no calcium variations between the IDH and 
control groups in their study. They reported that ionic variations were often 
nonspecific and similar in the great majority of dialysis patients with or without IDH. 
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2.7.6   Use and route of administration of erythropoietin-stimulating agents 
Erythropoietin is a hormone that controls erythropoiesis or red blood cell production. 
Erythropoietin is a protein-signalling molecule for red blood cell precursors in 
the bone marrow. It is primarily produced by interstitial fibroblasts in healthy kidneys. 
 
Recombinant human erythropoietin (rHuEpo) corrects the anaemia of ESRD. The 
dosage and frequency of rHuEpo prescribed to CKD patients depend on the severity 
of their anaemia, and rHuEpo is administered via an injection (subcutaneously or 
intravascular). However, intravenous administration has been associated with 
elevations in BP in dialysis patients and, interestingly, also with elevations in 
endothelin1 levels (Inrig et al., 2011).   
 
Buckner et al. (1990) reported that hypertension was observed as an adverse effect 
of increasing haematocrit. In their study, 44 out of 63 patients (70%) treated with 
rHuEpo had an increase in MAP greater than 10mmHg or required new or additional 
hypertensive medications.  
 
Interestingly, factors not associated with hypertension included the rate of rise of the 
haematocrit, the net rise in haematocrit, age, sex, the number of years on dialysis, 
the presence or absence of kidneys, smoking and the presence of pre-treatment 
hypertension. The authors’ conclusion (Buckner et al., 1990) was that increased 
blood viscosity or haemoconcentration-induced vasoconstriction (caused by 
erythropoietin treatment) could increase MAP, resulting in hypertension. 
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2.7.7   Possible removal of antihypertensive agents during dialysis 
As explained by Chazot et al. (2010) and Locatelli et al. (2010) in their review 
articles, specific drugs, including some antihypertensive medications, are removed 
by the dialysis procedure (relating to their molecular weight being small enough to 
move via diffusion/convection through the dialyser pores).  
 
The effect of drug removal on the occurrence of IDH has not been studied 
specifically. Removal of antihypertensive medications could lead to IDH. Although 
calcium channel blockers are not removed by the dialysis procedure, several 
angiotensin-converting enzyme inhibitors (captopril, enalapril, lisinopril, perindopril 
and ramipril) and betablockers (atenolol, metoprolol and nadolol) are significantly 
removed by dialysis, whereas others are not (fosinopril, propranolol, pindolol, 
esmolol, bisoprolol, carvedilol and acebutalol). Vasodilating agents are usually 
removed (minoxidil, diazoxide and nitroprusside), except for hydralazine and 
prazosin.  
 
In conclusion, an awareness of which drugs are extensively removed by dialysis is 
very important so that therapies can be adjusted if necessary in patients who 
develop IDH.  
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2.8   Management of intradialytic hypertension 
 
There have been no randomised trials regarding management of IDH, placing a 
heavy reliance on expert opinions.  
 
Management of IDH is directed at all of the aforementioned pathogenic mechanisms, 
but normalising volume overload and sodium balance is recommended as the first 
step in the management process (Locatelli et al., 2010). Table 2.4, as published by 
Prof Locatelli and co-workers (2010), summarises a comprehensive approach to the 
treatment of IDH. 
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Table 2.4: Potential strategies for the treatment of IDH 
 
Potential strategy Potential methods 
Reduce volume 
overload 
 Increase UF 
 
 Reduce cardiac output 
 
 Restrict dietary salt 
 
Control electrolyte 
changes 
 Ensure an adequate intradialytic sodium balance 
 
 Reduce dialysate calcium concentration 
 
Reduce sympathetic 
over activity 
 
 
 
 
 
 Administer angiotensin-converting enzyme 
inhibitors 
 
 Administer angiotensin II receptor blockers 
 
 Administer direct renin inhibitors 
 
 Administer adrenergic receptor blockers (α-
blockers and β-blockers) 
 
 Start patient on daily dialysis 
 
 Increase duration of dialysis 
 
Inhibit the RAAS  Administer angiotensin-converting enzyme 
inhibitors 
 
 Administer angiotensin II receptor blockers 
 
 Administer direct renin inhibitors 
 
Evaluate concurrent 
therapies 
 Consider whether the patient’s antihypertensive  
 
      drugs might be removed by dialysis 
 
(Adapted from Locatelli et al., 2010) 
 
More investigation is required to guide therapy, and to the researcher’s best 
knowledge, no research studies on IDH have been conducted among the South 
African HD population. Therefore, this study was conducted to shed light on the 
growing problem of intradialytic hypertension. 
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  3| METHODOLOGY 
 
 
3.1    Study location 
 
Four HD units in the Western Cape participated in this study: Tygerberg Academic 
Hospital, Panorama Kidney and Dialysis Centre, Athlone Kidney and Dialysis Centre 
and Winelands Kidney and Dialysis Centre.  
 
3.2    Study design 
 
A multicentre, cross-sectional study was conducted on chronic HD patients at four 
adult dialysis units in the Western Cape. IDH was defined as a rise of ≥10mmHg in 
systolic BP between pre-dialysis and post-dialysis in at least four out of six 
consecutive dialysis sessions. Participants deemed eligible for inclusion in the study 
were identified from HD charts by the primary investigator (PI). They were then 
approached by the PI, who obtained informed consent. Once informed consent had 
been obtained and no exclusion criteria had been found to be present, the patient 
was enrolled. A study identification number was allocated. 
 
By using a standard operating protocol, BP and pulse rate were measured pre-
dialysis, hourly on dialysis and 30 minutes after completion of dialysis. Weight and 
bio-impedance were determined pre-dialysis and post-dialysis using the BCM. 
Dialysis modality, hourly UF rates, intradialytic calcium and time-averaged sodium 
levels were also determined on dialysis (see Appendix A). All data extracted were 
captured onto a standardised data sheet (see Appendix B). This study formed part of 
a greater study: A cross-sectional study on intradialytic hypertension at four 
haemodialysis units in the Western Cape.  
 
The primary objective of the greater study was to determine the prevalence of IDH in 
the sample group. Secondary objectives included the secondary objectives of the 
current study as well as evaluation of antihypertensive drugs and erythropoietin use. 
Dialysability of these specific drugs was also investigated. 
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3.3    Study layout 
 
The layout of the current study is summarised below in Figure 3.1. 
 
 
Figure 3.1: Study layout 
Identified four haemodialysis units 
190 patients who met inclusion criteria participated 
Control group  
(136 patients) 
Pre-dialysis 
- Demographics 
- Weight, height, BMI, BP 
- Bioimpedance monitoring 
Dialysis 
- Hourly BP 
- Hourly UF rate (ml/hr) 
- Hourly UF (ml) 
- Total UF (ml) 
- Time-averaged serum                                                         
   sodium (mmol/L) 
- Dialysate calcium               
   concentration (mmol/L) 
- Dialysis modality  
Post-dialysis 
- Weight, BP 
- Bioimpedance monitoring 
- Total hours 
Analysed data 
IDH group  
(54 patients) 
Pre-dialysis 
- Demographics 
- Weight, height, BMI, BP 
- Bioimpedance monitoring 
Dialysis 
- Hourly BP 
- Hourly UF rate (ml/hr) 
- Hourly UF (ml) 
- Total UF (ml) 
- Time-averaged serum                    
   sodium (mmol/L) 
- Dialysate calcium   
  concentration (mmol/L) 
- Dialysis modality 
Post-dialysis 
- Weight, BP 
- Bioimpedance monitoring 
- Total hours 
Analysed data 
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3.4    Study population 
 
3.4.1    Number of subjects 
Two hundred and twenty-three patients were initially screened. Two hundred 
patients met the inclusion criteria. Three patients passed away before 
commencement of data collection, four received intravenous fluids of >200ml on 
dialysis, two patients’ BCM measurements were faulty and one patient’s HD circuit 
clotted prematurely. One hundred and ninety patients eventually participated in the 
study.  
 
3.4.2    Subject identification 
Patients deemed eligible for inclusion in the study were identified from the chronic 
dialysis programme. These patients received dialysis two to three times per week for 
3–4 hours per dialysis session. They were then approached by the PI, who obtained 
informed consent. Once informed consent had been obtained and no exclusion 
criteria had been found to be present, the patient was enrolled. A study identification 
number was allocated, and data were captured onto a standard data collection sheet 
(see Appendix B).   
 
The PI screened the dialysis charts of the enrolled patients and divided them into the 
two respective groups. A rise of ≥10mmHg in systolic BP between pre-dialysis and 
post-dialysis in at least four out of six consecutive dialysis sessions defined the IDH 
group. The patients who did not meet these criteria were categorised in the control 
group. 
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3.4.3    Inclusion and exclusion criteria 
 
3.4.3.1    Inclusion criteria 
 Men and women aged >18 years 
 On HD 2–3 times per week 
 Able to give informed consent 
 Able to read, write and understand English/Afrikaans/isiXhosa 
 
3.4.3.2    Exclusion criteria 
 Impossible to take BP by routine methods in the upper limbs 
 Unable to give informed consent 
 Patients who received intravenous fluids >200ml and/or intravenous 
antibiotics for intercurrent acute illness 
 Contraindications pertaining to bio-impedance monitoring (pre-existing 
implanted cardiac devices such as pacemakers and cardioverter defibrillators; 
amputees) 
 Pregnant patients  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Central University of Technology, Free State
 
36 
3.5    Measurements 
 
The following measurements were performed on the patients: 
 
3.5.1   Blood pressure 
Systolic and diastolic BP was measured via electronic, calibrated BP modules 
manufactured by Fresenius Medical Care Deutschland GmbH. The BP modules are 
a standard fixture on the respective dialysis machines, and each is fitted with an 
adult-sized BP cuff with an internal bladder measuring 12cm. The systolic and 
diastolic BP measurements were taken by placing the cuff directly on the brachial 
artery on the medial side of the upper arm.  
 
3.5.2    Bio-impedance monitoring 
Four electrodes were attached to the patient: two to the anterior part of the arm, with 
one electrode on the wrist and one electrode on the hand (4cm apart), and two to the 
anterior part of the leg, with one electrode on the ankle and one electrode on the foot 
(4cm apart). The arm and leg used for measurements were on the same side of the 
body (see Figure 3.2). 
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Figure 3.2: Body composition monitoring 
(BCM product folder, Fresenius Medical Care Deutschland GmbH, 2007) 
 
Bio-impedance was measured using the BCM before dialysis and 30 minutes after 
dialysis.  
 
3.5.3    Interdialytic weight gain and body mass index 
Patients were weighed on a designated electronic scale at the respective units. The 
same scale was used pre-dialysis and post-dialysis for each patient. The results 
were displayed in kilogram (kg), up to one decimal. 
 
Interdialytic weight gain was calculated according to the following formula: 
IDWG (kg) = pre-dialysis weight (kg) - post-dialysis weight (kg) of previous session.    
IDWG was subsequently set as total UF volume (ml) goal for the dialysis session on 
that day. 
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Body mass index was calculated according to the following formula: 
BMI (kg/m²) = weight (kg) ÷ height (m2)   
 
Patients’ height was measured using a fixed measuring tape calibrated in 
centimetres (cm), in the respective units. 
 
3.5.4    Time-averaged serum sodium concentration on haemodialysis 
Serum sodium concentrations were measured by the Online Clearance Monitor 
(OCM), which is a standard feature on the 4008S and 5008S HD machines from 
Fresenius Medical Care, used at all the dialysis units.   
 
The OCM determines sodium concentrations at the dialysate inflow and outflow of 
the dialyser by monitoring conductivity through conductivity cells that are situated at 
the inflow and outflow points, as shown in Figure 3.3.  
 
 
 
 
Figure 3.3: Serum sodium measurement 
(OCM product folder, Fresenius Medical Care, 2003) 
 
Qb = blood flow (ml/min)  Cb = conductivity in the blood (mS/cm) 
Qd = dialysate flow (ml/min)   Cd = conductivity in the dialysate (mS/cm) 
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The difference between the values of the two conductivity cells in relation to the 
dialysate flow rate shows the rate of flow of sodium into or out of the patient. By 
using the value for clearance previously measured by the OCM, the serum 
concentration of sodium can be calculated. In this way, the OCM derives a value for 
serum sodium from each clearance measurement every 25 minutes while the patient 
is on dialysis. The result is adjusted by the machine’s software using correction 
factors so that the displayed value on the dialysis machine reflects the patient’s 
serum sodium (mmol/L). The accuracy of the result is equivalent to that obtained by 
means of flame photometry assay (a laboratory method for measuring sodium and 
potassium in biological fluids). 
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3.6    Data collection 
 
Data were collected according to the standard operating protocol detailed in 
Appendix A. 
 
3.7    Statistical analysis 
 
The Centre for Statistical Consultation at Stellenbosch University was consulted. 
Descriptive analysis was performed looking at means ± standard deviations, 
medians and interquartile ranges, histograms, box plots, frequencies, proportions, 
and so forth. Both unadjusted and adjusted analyses with multilinear regression (for 
age, gender and socioeconomic status) were used for dry weights, antihypertensive 
drug use, bio-impedance monitoring, erythropoietin-stimulating agent therapy and 
time-averaged sodium concentrations. Where data had a normal distribution, t-tests 
for the mean were utilised, whereas non-normally distributed data were analysed 
using Mann-Whitney-Hugh tests. A significant p-value was set at p≤0.05.  To achieve 
a standard precision of 5% (95% CI), a sample size of 190 patients was needed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Central University of Technology, Free State
 
41 
3.8    Ethical aspects and good clinical practice 
 
3.8.1    Ethical clearance 
Approval from the Health Research Ethics Committee from Stellenbosch University 
was granted on 3 December 2012 for the greater study that the current study formed 
part of: A cross-sectional study on intradialytic hypertension at four haemodialysis 
units in the Western Cape with ethics reference number: S12/10/264 (see Appendix 
C). 
 
This study was registered with Clinical Trials.gov in the United States of America, 
registration number NCT01916668 (see Appendix D). 
 
The greater study was also presented as a poster presentation at the World 
Congress of Nephrology in March 2015, abstract number WCN15-0447 (see 
Appendix E). 
 
3.8.2    Safety variables 
3.8.2.1    Project and patient safety 
The study posed no safety risks as it was an observational study and no changes 
were made to the patients’ existing dialysis prescription. Body composition 
monitoring is analogous to electrocardiograph monitoring. The study did not have 
any impact on the routine standard of care.  
 
3.8.2.2    Premature discontinuation of the study 
The study was not discontinued by the PI or any of the study leaders due to breach 
of confidentiality or any unethical procedures. 
 
3.8.2.3    Good clinical practice/quality assurance 
All clinical work conducted under this protocol was subjected to the Good Clinical 
Practice Guidelines (The Principles of International Conference on Harmonisation: 
Good Clinical Practice, 1996). 
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The Declaration of Helsinki’s (2002) Basic Principle Number 3 was adhered to in this 
study. It states that research should be conducted only by scientifically qualified 
people and under the supervision of adequately qualified people (World Medical 
Association, 2002).    
 
3.8.3    Financial implications for the patient 
There were no financial implications for the patients, and recruitment was voluntary. 
 
3.8.4    Withdrawal criteria 
No patient withdrew from the study during the trial period. Patients had the right to 
withdraw from the study at any time, irrespective of the reason(s), without detriment 
to their medical care at the time or in the future. Elimination of a patient from the 
study would not have resulted in any penalty. 
 
3.8.5    Subject information and informed consent 
Written informed consent was obtained in the home language of the patient. Consent 
forms were available in English, Afrikaans and isiXhosa. In the case of participants 
who were unable to give written consent, informed consent was witnessed. 
  
The following were explained to the participants: the nature of the study, any 
procedures involved, potential risks and benefits, the right to withdraw from the study 
without incurring any penalty, procedures to maintain confidentiality and that 
participation were completely voluntary. 
 
3.8.6    Confidentiality  
In accordance with the Declaration of Helsinki of 2002, data were collected in a 
confidential area and a coding system (unique study identification number) was used 
to maintain anonymity. Permission to collect data from dialysis and prescription 
charts was obtained from the participants. Data were stored on the PI’s computer 
alone, which was password protected. All documents including data collection sheets 
and identification coding lists were stored in a locked cupboard to which only the PI 
had access. 
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  4| RESULTS 
 
Two hundred and twenty-three patients were initially screened at four dialysis 
units. Two hundred patients who met the inclusion criteria were selected. 
However, three patients passed away before data collection commenced, four 
received intravenous fluids of >200ml on dialysis, two patients’ BCM 
measurements were faulty and one patient’s dialysis circuit clotted prematurely.  
One hundred and ninety patients eventually participated in the study (see Figure 
4.1). 
 
Intradialytic hypertension was defined as a rise of ≥10mmHg in systolic BP 
between pre-dialysis and post-dialysis in at least four out of six consecutive 
dialysis sessions. 
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Figure 4.1: Patient participation  
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4.1    Primary results 
 
The primary results showed that there was a trend toward statistical significance 
regarding pre-dialysis OH as measured by whole body bio-impedance (mean 
pre-dialysis OH was 2.6L [95% CI 1.7–3.4] vs. 1.8L [95% CI 1.4–2.10]; p=0.06) in 
IDH cases compared to controls. There was also a trend toward statistical 
significance in post-dialysis OH as measured by whole body bio-impedance 
(mean post-dialysis OH was 0.79L [95% CI -0.04–1.62] vs. -0.17L  
[95% CI 0.52–0.18]; p=0.06), as shown in Figure 4.2. 
 
 
Figure 4.2: Pre-dialysis and post-dialysis OH (L) in IDH group vs. control 
group 
  
The results regarding percentage ECW correlated with the OH results, as shown 
in Figure 4.3.  
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Pre-dialysis percentage ECW did not achieve a significant result as measured by 
whole body bio-impedance (mean pre-dialysis percentage ECW was 12.3% [95% 
CI 8.3–16.3] vs. 9.6% [95% CI 7.8–11.5]; p=0.12) in IDH cases compared to 
controls. 
The post-dialysis results showed statistical significance with the IDH group’s 
mean percentage ECW decreasing to 3.5% (95% CI -1.4–8.5) compared to the 
control group’s mean percentage ECW of -1.4% post-dialysis (95% CI -3.7–0.8); 
p=0.04 (see Figure 4.3). 
 
 
Figure 4.3: Pre-dialysis and post-dialysis percentage ECW in IDH group vs. 
control group 
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4.2    Pre-dialysis results 
 
No differences were identified regarding mean age (57.1 years vs. 55.1 years;  
p=0.42), gender (men 53.7% vs. 59.5%; p=0.46) and race (p=0.23) in the IDH 
group as compared with the controls (see Table 4.1). 
 
Table 4.1: Pre-dialysis results: Baseline demographic results 
Pre-dialysis IDH group 
(n=54) 
Control group 
(n=136) 
p-value 
Demographics    
Mean age (years) 57 55 0.42 
Male (%) 53 59 0.46 
White (%) 46 33 0.23 
Black (%) 11 14 0.23 
Coloured (%) 42 52 0.23 
         p<0.05 indicates a statistically significant difference 
 
There were no differences in mean weight (74kg vs. 77kg; p=0.26) or BMI  
(26kg/m² vs. 27kg/m²; p=0.55). There was a statistically significant difference in 
mean systolic BP pre-dialysis (159mmHg vs. 150mmHg; p=0.04) in the IDH 
group as compared with the control group (see Table 4.2). 
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Table 4.2: Pre-dialysis results: Clinical data 
Pre-dialysis IDH group 
(n=54) 
Control group 
(n=136) 
p-value 
Clinical data    
Mean weight (kg) 74 77 0.26 
Mean BMI (kg/m²) 26 27 0.55 
Mean systolic BP (mmHg) 159 150 0.04 
Mean diastolic BP (mmHg) 76 73 0.41 
MAP (mmHg) 103 99 0.11 
p<0.05 indicates a statistically significant difference 
BMI = body mass index 
BP = blood pressure 
MAP = mean arterial pressure  
 
Pre-dialysis OH and percentage ECW results are discussed in the Primary 
results (4.1) section and depicted in Figures 4.2 and 4.3. 
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4.3    Dialysis results 
 
Mean systolic BP showed a significant difference between the two groups  
(158mmHg vs. 136mmHg; p<0.001) on dialysis (see Figure 4.4). 
 
 
Figure 4.4: Mean hourly systolic BP during dialysis in IDH group vs. control 
group 
 
The hourly UF rate was lower throughout the four-hour dialysis procedure in the 
IDH group compared to the control group. The difference in mean UF rate  
(609ml/hr vs. 641ml/hr) was not statistically significant (p=0.52).  
 
There was no statistically significant difference in mean total UF volume in the 
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Figure 4.5: Fluid removal on dialysis: Mean UF rate per hour over four 
hours (to the left) and total UF over four hours (to the right) for IDH group 
vs. control group 
 
There were no differences in mean time-averaged sodium concentrations  
(138.3mmol/L vs. 138.4mmol/L; p=0.72) or mean dialysate calcium 
concentrations (1.34mmol/L vs. 1.36mmol/L; p=0.45). There was no statistically 
significant difference in the proportion of patients on the two dialysis modalities 
(HD:HDF): IDH group (19%:81%) versus control group (21%:79%) (p=0.66), as 
shown in Table 4.3. 
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Table 4.3: Dialysis results: Clinical data 
Dialysis IDH group 
(n=54) 
Control group 
(n=136) 
p-value 
Clinical data    
Mean time-averaged sodium (mmol/L) 138.3 138.4 0.72 
Dialysate related    
Mean dialysate calcium (mmol/L) 1.34 1.36 0.45 
Dialysis modality    
HD (%) 19 21 0.66 
HDF (%) 81 79 0.66 
 p<0.05 indicates a statistically significant difference 
 HD = haemodialysis 
 HDF = haemodiafiltration 
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4.4    Post-dialysis results 
 
Mean systolic BP was significantly different at the end of dialysis between the 
two groups (155mmHg vs. 135mmHg; p<0.001) (see Figure 4.4); however, there 
was no significant difference in mean weight post-dialysis (72kg vs. 76kg;  
p=0.31) in the IDH group as compared with the control group, as shown in Table 
4.4. 
 
Table 4.4: Post-dialysis results: Clinical data 
Post-dialysis IDH group 
(n=54) 
Control group 
(n=136) 
p-value 
Clinical data    
Mean systolic BP (mmHg) 155 135 <0.001 
Mean diastolic BP (mmHg) 79 70 0.004 
MAP (mmHg) 104 92 <0.001 
Mean weight (kg) 72 76 0.31 
 p<0.05 indicates a statistically significant difference 
        BP = blood pressure 
  MAP = mean arterial pressure 
 
The total number of hours on dialysis per week was less in the IDH group as 
compared to the control group (10.85 hours vs. 11.11 hours; p=0.29); however, 
this did not reach statistical significance, as shown in Figure 4.6. 
 
 
© Central University of Technology, Free State
 54 
 
Figure 4.6: Mean total hours per week on dialysis for IDH group vs. control 
group 
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  5| DISCUSSION AND CONCLUSION 
 
5.1   Primary results 
 
The primary results showed that there was a trend toward statistical significance 
with regard to pre-dialysis OH status (p=0.06) as well as post-dialysis OH status 
(p=0.06). The IDH patients, however, showed no clinical features of fluid 
overload. Several other studies have also found that subclinical volume overload 
is associated with IDH (Cirit et al., 1995; Gunal et al., 2002). Agarwal et al. 
(2010) reported a post-dialysis weight reduction of 0.9kg over four weeks that 
resulted in a drop of 6.9mmHg (p=0.016) in systolic intradialytic BP. 
 
Chronic fluid overload results from escalating fluid accumulation when 
interdialytic fluid gain is not removed on individual dialysis sessions due to 
possible hemodynamic instability or other complications such as cramping.  
 
When combined with non-adherence to interdialytic salt and fluid intake, this may 
result in small gains of excess fluid over a long period of time (Levy et al., 2010).  
When dry weight is not assessed regularly and managed effectively, subclinical 
fluid overload can accumulate in such a way that it may present serious clinical 
consequences later such as IDH (see Figure 4.5), ambulatory hypertension and 
left ventricular hypertrophy as reported by London (2003).  Subclinical fluid 
overload produces no symptoms or signs such as pedal oedema, hypertension, 
cardiac dysfunction or shortness of breath and is often overlooked in dialysis 
patients.   
 
Onofriescu et al. (2014) reported a similar concern when dry weight in dialysis 
patients was assessed according to clinical methods rather than bio-impedance 
measurements. In this study 131 patients were followed up over a period of 3.5 
years.  
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Relative fluid overload decreased from 9.52% to 7.46% (p=0.03) in the bio-
impedance group while the control group actually gained fluid from 10.30% to 
11.24% in the same period. This supports the evidence that clinical assessment 
of fluid overload is not always reliable. 
 
Furthermore, the extreme fluid and consequent volume shifts that dialysis 
patients are exposed to during UF, cause significant cardiovascular strain 
(London, 2003). When this is combined with co-morbidities such as diabetes 
mellitus, progression of cardiovascular disease is the unfortunate outcome. 
Antlanger et al. (2013) reported a similar conclusion that chronic fluid overload 
was associated with higher mortality rates in dialysis patients and could be used 
as a biomarker for cardiovascular risk in the HD population. Similar results for 
subclinical fluid overload were also obtained by numerous previous studies, as 
reported by Cirit et al. (1995), Agarwal et al. (2010) and Nongnuch et al. (2014).  
 
Cirit et al. (1995) reported on patients who presented with marked cardiac 
dilatation and high blood pressure, but most did not have signs of oedema 
associated with hypervolaemia. They were treated with repeated intense UF.  
After a variable time period, all the patients became normotensive without 
additional medication.   
 
A recent publication by Nongnuch et al. (2014) compared the ratio of ECW to 
TBW. The authors performed a prospective audit involving 531 HD patients who 
also underwent bio-impedance monitoring. Their findings were that patients who 
had a rise in BP post-dialysis had an elevated ECW: TBW ratio before and after 
dialysis. Their suggestion was that patients who had increased BP post-dialysis 
were most likely to be volume overloaded. In this study, the IDH group’s average 
IDWG was 187.96ml less compared to that of the control group (p=0.32), as 
shown in Figure 4.5.  
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The results of the bio-impedance monitoring however showed that the IDH group 
had higher OH (L) pre-dialysis (see Figure 4.2) and subsequent elevated 
percentage ECW (see Figure 4.3) compared to the control group (p=0.12). This 
OH was subclinical and the patients presented with no signs of fluid overload. 
The IDH group’s mean pre-dialysis percentage ECW was 12.3% compared to the 
control group which was slightly less at 9.6% ECW (see Figure 4.3). Our post-
dialysis percentage ECW result showed statistical significance with the IDH 
group’s mean decreasing to 3.5% compared to the control group’s mean 
percentage ECW of -1.4% (p=0.04), as depicted in Figure 4.3. This signifies that 
patients with IDH did not reach dry weight post-dialysis which may be related to 
shorter total dialysis duration. 
 
The percentage ECW as measured by the BCM may not necessarily reflect OH, 
as the distribution of the fluid in this compartment may vary according to 
nutritional status, specifically due to variability of serum albumin levels, which 
was not included in this study.    
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5.2   Pre-dialysis results 
 
There was no significant difference between the two groups in terms of patients’ 
age, gender or race distribution (see Table 4.1). The mean age of the study 
population was 56 years which was similar to the mean age of 54 years as 
reported by Agarwal et al. (2010) and Van Buren et al. (2011).  However, in one 
of the dialysis units who contributed to patient recruitment, the prevalence of IDH 
was 70%. The mean age of patients in this unit was 65 years. It may be that 
older age contributes to IDH due to greater vascular stiffness. 
 
Our study population was overweight as measured by BMI. The BMI results for 
both groups were both above 25kg/m², with the IDH group at 26kg/m² versus 
27kg/m² for the control group. Antlanger et al. (2013) reported a negative 
association regarding BMI and fluid overload, particularly with a BMI >30kg/m².  
 
Although the difference in BMI results for this study was not statistically 
significant, it contradicts Antlanger’s findings as the IDH group showed a trend 
towards fluid overload despite a lower BMI compared to the control group (see 
Table 4.2).  
 
There was a statistically significant difference in mean systolic BP in the IDH 
group versus the control group. The IDH group had a 9mmHg higher systolic BP 
pre-dialysis (see Table 4.2). This phenomenon may be explained by the position 
patients find themselves on the Frank Starling curve. In the case of the IDH 
group, their position may be to the right of the Starling curve as opposed to the 
control group which may be to the left, similar to the findings reported by Gunal et 
al. (2002). However, Van Buren et al. (2011) and Nongnuch et al. (2014) 
reported lower pre-dialysis systolic BP in the IDH group compared to the control 
group.  
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5.3   Dialysis results 
 
There was a statistical significant difference between the two groups with regards 
to hourly systolic BP changes during dialysis. Figure 4.4 reveals the increase in 
systolic BP in the IDH group while the control group’s systolic BP decreased 
during the dialysis procedure. 
 
However, the decrease in systolic BP was greater in the control group as 
compared with the rise in systolic BP in the IDH group. This is indicative of 
resistance of the IDH group to UF. It may be that the control group is closer to 
their dry weights at the start of dialysis as compared to the IDH group. 
 
As the mean UF rate per hour (see Figure 4.5) and subsequent total mean UF 
(see Figure 4.5) for the IDH group during the dialysis session were lower 
compared to the control group, an increased sympathetic response to 
ultrafiltration is unlikely to be a major contributing factor. Chou et al. (2006) 
reported that patients with IDH had an increase in peripheral vascular resistance 
(PVR) but this could not be explained by an increase in sympathetic output. 
However, the increase in PVR may be explained by an imbalance of nitric oxide 
and endothelin-1 levels.  
 
According to the National Kidney Foundation - Kidney Disease Outcomes Quality 
Initiative guidelines published in 2005 (NKF KDOQI, 2005), a positive sodium 
balance is the main mechanism of extracellular fluid overload and hypertension 
in dialysis patients.   
 
There was no difference between the two groups with regard to time-averaged 
sodium concentration in this study: in the IDH group, serum sodium of 
138.3mmol/L compared to the control group with serum sodium at 138.4mmol/L 
(p=0.72), as shown in Table 4.3.  
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However, a more reliable marker of sodium gain would have been to assess the 
patients’ serum sodium concentration pre-dialysis to determine if a concentration 
gradient was present for the absorption of sodium into the plasma during dialysis 
(Locatelli et al., 2010).  Nongnuch et al. (2014) reported no difference in the 
dialysate to serum sodium gradient as well as pre-serum and post-serum 
sodium.  
 
No statistical significance was achieved between the two groups with the mean 
dialysate calcium concentrations (p=0.45). The dialysate calcium level tends to 
equilibrate with the ionized fraction of the serum calcium (1.1mmol/L to 
1.5mmol/L). Serum calcium can be classified in 3 categories: protein bound 
(40%), complexes (14%) and ionized (46%). The ionized and calcium complexes 
are dialyzable (Sam et al., 2006). Sam et al. (2006) further reported that dialysate 
with a calcium concentration of 1.63mmol/L or higher could lead to transient 
hypercalcaemia with symptoms of nausea and vomiting. 
 
It has been shown that the use of a low calcium dialysate (1.25mmol/L) is 
associated with a mild but significant decline in the mean BP during dialysis 
(Sam et al., 2006). The decline in BP is mediated by a decrease in cardiac 
contractility due to lower serum calcium levels.  
 
Chou et al. (2006) and Nongnuch et al. (2014) reported similar results to this 
study, whereby there were no calcium variations between the IDH and control 
groups.  
 
A similar distribution of the groups between the two dialysis modalities, HD and 
HDF (p=0.66), was observed, as shown in Table 4.3.  
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Canaud et al. (2000) and Maduell et al. (2013) both reported that HDF was a 
more effective form of dialysis, with a 33% lower risk of cardiovascular mortality 
as well as more haemodynamic stability intradialytically compared to 
conventional HD in terms of intradialytic hypotension.  However, nothing has 
been reported in favour of HDF compared to HD where intradialytic hypertension 
is concerned.     
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5.4   Post-dialysis results 
 
A concerning factor is that the IDH group’s mean effective time on dialysis per 
week was less than the control group’s (see Figure 4.7). The IDH group’s dialysis 
time per week was 10 hours 51 minutes versus the control group at 11 hours 6 
minutes (p=0.29).  This did not reach statistical significance; however, it was 
suggested that this may be clinically significant as this can result in less UF in the 
long term. Nongnuch et al. (2014) also found no major differences in dialysis 
prescription (including time on dialysis) when comparing the IDH to the control or 
hypotensive groups in their study.  
 
The European Best Practice Guidelines (2007) clearly state in Guideline 1.1 
“Dialysis should be delivered at least 3 times per week and the total duration 
should be at least 12 hours per week, unless supported by significant renal 
function.” (EBPG, 2007).   
 
Both the control group and the IDH group in this study received mean weekly 
hours of less than 12 hours on dialysis, however when the hours are calculated 
on a monthly basis, the IDH group received 60 minutes less dialysis compared to 
the control group. Less dialysis equals less UF and thus excess fluid will 
accumulate over time as discussed previously.  
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5.5   Limitations of the study 
 
This study had numerous limitations: 
 The study was not powered to find a difference in fluid status, as this was 
a secondary outcome of a greater study that was powered to find a 
prevalence of IDH of 15%. 
 Sodium and calcium gradients were not determined. 
 Only a single dialysis session for each patient was investigated. 
 The midweek dialysis session was investigated in the majority of the 
patients. However, a small number of patients received dialysis twice a 
week and did not attend midweek sessions. This resulted in a longer 
interdialytic period, which would have affected the IDWG. 
 Other causes of fluid overload (for example cardiac disease or ongoing 
nephritic syndrome) were not excluded. 
 Dietary indiscretions by the patients were not excluded at the time. 
Nutritional status, especially serum albumin levels, may influence 
movement of fluid between the fluid compartments. 
 The BCM’s contraindications limited the number of patients who met the 
inclusion criteria; for example, patients with amputations and pacemakers 
needed to be excluded as they are contraindicated in whole body bio-
impedance monitoring. 
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5.6    Recommendations 
 
A cross sectional IDH study, involving a larger sample group to determine the 
difference in hydration status would be a far more reliable approach to confirm 
the causes of IDH as reported by this study and several others to date (Cirit et 
al., 1995; Gunal et al., 2002; Chou et al., 2006; Agarwal et al., 2010; Nongnuch 
et al., 2014). 
 
Investigative parameters should include data as captured by this study as well as 
the following: 
 Cardiac history 
 Nutritional status 
 Segmental bio-impedance measurement 
 Serum and dialysate sodium gradient 
 Serum and dialysate calcium gradient 
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5.7    Conclusion 
 
There is a statistically significant trend towards a difference in hydration status 
between patients who develop IDH compared to patients with stable BP on 
dialysis.  Similar results were obtained by Cirit et al. (1995), Gunal et al. (2002), 
Agarwal et al. (2010) and Nongnuch et al. (2014).  
 
In conclusion, IDH may be due to subclinical fluid overload as measured by bio-
impedance spectroscopy. 
 
In practice, accurate fluid assessment via bio-impedance spectroscopy is 
paramount to effectively assess HD patients’ overhydration status. Subsequently 
patients can be maintained in an euvolaemic state via adequate UF and 
ultimately hypertension can be managed more effectively. This could contribute 
significantly to minimise hypertension as a cardiovascular risk factor in HD 
patients.   
 
 
 
 
 
 
 
 
 
 
 
 
 
© Central University of Technology, Free State
 66 
  | BIBLIOGRAPHY 
 
Agarwal, R. & Light, R.P. 2010. Intradialytic hypertension is a marker of volume 
excess. Nephrology Dialysis Transplantation, October 25 (10):3355–3361.  
 
Antlanger, M., Hecking, M., Haidinger, M., Werzowa, J., Kovarik, J., Paul, G., Eigner, 
M., Bonderman, D., Hörl, W.H. & Säemann, M.D. 2013. Fluid overload in 
hemodialysis patients: A cross-sectional study to determine its association with 
biomarkers and nutritional status. BMC Nephrology, (14):266. 
 
Buckner, F.S., Eschbach, J.W., Haley, N.R., Davidson, R.C. & Adamson, J.W. 1990. 
Hypertension following erythropoietin therapy in anemic hemodialysis patients. 
American Journal of Hypertension, December 3 (12 Pt 1):947–955.  
 
Canaud, B., Bosc, J.Y., Leray-Moragues, H., Stec, F., Argiles, A., Leblanc, M. & 
Mion, C. 2000. Online haemodiafiltration: Safety and efficacy in a long-term clinical 
practice. Nephrology Dialysis Transplantation, 15 (1):60–67. 
 
Chazot, C. & Jean, G. 2010. Intradialytic hypertension: It is time to act. Nephron 
Clinical Practice, 115 (3):182–188.  
 
Chou, K.J., Lee, P.T., Chen, C.L., Chiou, C.W., Hsu, C.Y., Chung, H.M., Liu, C.P. & 
Fang, H.C. 2006. Physiological changes during hemodialysis in patients with 
intradialysis hypertension. Kidney International, May 69 (10):1833–1838.  
 
Cirit, M., Akcicek, F., Terzioglu, E., Soydas, C., Ok, E., Ozbasli, C.F., Basci, A. & 
Mees, E.J. 1995. 'Paradoxical' rise in blood pressure during ultrafiltration in dialysis 
patients. Nephrology Dialysis Transplantation, 10 (8):1417–1420.  
 
Covic, A., Bejan, C., Klein, C., Cretu, O., Ionescu, D. & Himmele, R. 2009. Body 
composition monitoring (BCM) in peritoneal dialysis patients: Objective assessment 
of overhydration, blood pressure and nutritional status. Peritoneal Dialysis 
International, 29 (10):S21–S22.   
© Central University of Technology, Free State
 67 
 
Davids, M., Marais, N. & Jacobs, J. 2014. South African Renal Registry Annual 
Report 2012. South African Renal Society: 1–18 [Online]. Available: 
http://www.kidney-international.org [2014, April 23].  
 
Denhaerynck, K., Manhaeve, D., Dobbels, F., Garzoni, D., Nolte, C. & De Geest, S. 
2007. Prevalence and consequences of nonadherence to haemodialysis regimens. 
American Journal of Critical Care, 16 (3):222–235. 
 
European Best Practice Guidelines (EBPG). 2007. EBPG guideline on dialysis 
strategies. Nephrology Dialysis Transplantation, May 22 (Supplement 2):ii5–ii21. 
 
Fourtounas, C. 2010. "Malignant" intradialytic hypertension: A severe form of 
intradialytic hypertension. American Journal of Kidney Diseases, August 56 (2):418–
419. 
 
Fresenius Medical Care Deutschland GmbH. 2003. Online clearance monitoring: 
Dialysis efficiency becomes measurable. Bad Homburg: 1–28.  
 
Fresenius Medical Care Deutschland GmbH. 2004. Sodium and UF profiles in 
dialysis: Structure, application and effect. Bad Homburg: 1–68. 
Fresenius Medical Care Deutschland GmbH. 2007. Online haemodiafiltration – the 
therapy guide. Bad Homburg: 1–64. 
 
Fresenius Medical Care Deutschland GmbH. 2012. Living with dialysis: Nephrocare, 
helping you to live life to the full. Bad Homburg: 1–72. 
 
Gunal, A.I., Karaca, I., Celiker, H., Ilkay, E. & Duman, S. 2002. Paradoxical rise in 
blood pressure during ultrafiltration is caused by increased cardiac output. Journal of 
Nephrology, January–February 15 (1):42–47.  
 
 
 
© Central University of Technology, Free State
 68 
Inrig, J.K., Oddone, E.Z., Hasselblad, V., Gillespie, B., Patel, U.D., Reddan, D., Toto, 
R., Himmelfarb, J., Winchester, J.F., Stivelman, J., Lindsay, R.M. & Szczech, L.A. 
2007. Association of intradialytic blood pressure changes with hospitalization and 
mortality rates in prevalent ESRD patients. Kidney International, March 71 (5):454–
461. 
 
Inrig, J.K., Patel, U.D., Toto, R.D. & Szczech, L.A. 2009. Association of blood 
pressure increases during hemodialysis with 2-year mortality in incident 
hemodialysis patients: A secondary analysis of the Dialysis Morbidity and Mortality 
Wave 2 Study. American Journal of Kidney Diseases, November 54 (5):881–890.  
 
Inrig, J.K., Van Buren, P., Kim, C., Vongpatanasin, W., Povsic, T.J. & Toto, R.D. 
2011. Intradialytic hypertension and its association with endothelial cell dysfunction. 
Clinical Journal of the American Society of Nephrology, August 6 (8):2016–2024.  
Kidney Disease: Improving Global Outcomes (KDIGO). 2009. Clinical practice 
guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney 
disease - mineral and bone disorder. Kidney International Supplements, (113):s1–
132 [Online]. Available: http://www.kidney-international.org [2014, June 7]. 
 
Kidney Disease: Improving Global Outcomes (KDIGO). 2012a. Clinical practice 
guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney 
disease. Kidney International Supplements, (3:1):s1–150 [Online]. Available: 
http://www.kidney-international.org [2014, June 3]. 
 
Kidney Disease: Improving Global Outcomes (KDIGO). 2012b. Clinical practice 
guideline for the management of blood pressure in CKD. Kidney International 
Supplements, (2):337–414 [Online]. Available: http://www.kidney-international.org 
[2014, June 3].  
 
Leggat, J.E., Orzol, S., Hulbert-Shearon, T.E., Golper, T.A., Jones, C.A., Held, C.J. & 
Port, F.K. 1998. Noncompliance in hemodialysis: Predictors and survival analysis. 
American Journal of Kidney Disease, July 32 (1):139–145.  
 
© Central University of Technology, Free State
 69 
Levin, A., Singer, J., Thompson, C.R., Ross, H. & Lewis, M. 1996. Prevalent left 
ventricular hypertrophy in the pre-dialysis population: Identifying opportunities for 
intervention. American Journal of Kidney Disease, 27 (3):347–354. 
 
Levy, J., Brown, E., Daley, C. & Lawrence, A. 2010. Oxford handbook of dialysis. 3rd 
edition. New York: Oxford University Press. p. 6, 26, 77. 
 
Locatelli, F., Cavalli, A. & Tucci, B. 2010. The growing problem of intradialytic 
hypertension. Nature Reviews Nephrology, January 6 (1):41–48. 
 
Locatelli, F., Covic, A., Chazot, C., Leunissen, K., Luño, J. & Yaqoob, M. 2004. 
Optimal composition of the dialysate, with emphasis on its influence on blood 
pressure. Nephrology Dialysis Transplantation, April 19 (4):785-–796. 
 
London, G.M. 2003. Cardiovascular disease in chronic renal failure: 
Pathophysiologic aspects. Seminars in Dialysis, 16 (2):85–94.   
 
Maduell, F., Moreso, F., Pons, M., Ramos, R., Mora-Macia, J., Carreras, J., Soler, J., 
Torres, F., Campistol, J.M. & Martinez-Castelao, A. 2013. High-efficiency post 
dilution online haemodiafiltration reduces all-cause mortality in haemodialysis 
patients. Clinical Journal of the American Society of Nephrology [Online] (24):1–11. 
Available: http://www.jasn.org [2013, February 19]. 
 
Moissl, U., Wabel, P., Chamney, P.W., Levin, N.,Bosy-Westphal,A., Korth, O., Miller, 
M.J., Ellegird,L., Malmros, V., Kaitwatcharachai, C., Kuhlmann, M.K., Zhu, F. & 
Fuller, N.J. 2006. Body fluid volume determination via body composition 
spectroscopy in health and disease. Physiological Measurement, September 27 
(9):921–933. 
 
 
 
 
 
 
© Central University of Technology, Free State
 70 
National Kidney Foundation: Kidney Disease Outcomes Quality Initiative (NKF 
KDOQI) guidelines. 2005. KDOQI Clinical practice guidelines for cardiovascular 
disease in dialysis patients. Section II: Guidelines on management of cardiovascular 
risk factors, guideline 12: Blood pressure. [Online] Available:   
http://www2.kidney.org/professionals/KDOQI/guidelines_cvd/guide12.htm  
[2013, October 2] 
 
Nongnuch, A., Campbell, N., Stern, E., El-Kateb, S., Fuentes, L. & Davenport, A. 
2014. Increased post-dialysis systolic blood pressure is associated with extracellular 
overhydration in hemodialysis patients. Kidney International [Online] (7):276–282. 
Available: http://www.nature.com [2014, August 2]. 
 
Onofriescu, M., Hogas, S., Voroneanu, L., Apetrii, M., Nistor, I., Kanbay, M. & Covic, 
A.C. 2014. Bio-impedance guided fluid management in maintenance haemodialysis: 
A pilot randomized controlled trial. American Journal of Kidney Diseases, July 64 
(1):111–118. 
 
Sam, R., Vasseemudin, M., Leong, W.H., Rogers, B.F., Kjellstrand, C.M. & Ing, TS. 
2006. Composition and clinical use of hemodialysates. Hemodialysis International, 
January 10 (1):15–28. 
 
Teng, J., Tian, J., LV W, Zhang, X.Y., Zou, J.Z., Fang, Y., Yu, J., Shen, B., Liu, Z.H. 
& Ding, X.Q. 2014. Inappropriately elevated endothelin1 plays a role in the 
pathogenesis of intradialytic hypertension. Hemodialysis International [Online] 
(12238):1–8. Available: http://www.http://onlinelibrary.wiley.com/doi/10.1111/ 
hdi.12238/pdf [2014, October 30]. 
 
The Principles of International Conference on Harmonisation: Guideline for Good 
Clinical Practice. 1996. [Online] E6 (R1):1–59. Available: 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/
E6_R1_Guideline.pdf [2013, October 2]. 
 
© Central University of Technology, Free State
 71 
Van Buren, P.N., Kim, C., Toto, R. & Inrig, J.K. 2011. Intradialytic hypertension and 
the association with interdialytic ambulatory blood pressure. Clinical Journal of the 
American Society of Nephrology, July (6):1684–1691. 
 
Wabel, P., Chamney, P., Moissl, U. & Jirka, T. 2009. Importance of whole body bio-
impedance spectroscopy for the management of fluid balance. Blood Purification, 
27:75–80. 
 
World Medical Association Declaration of Helsinki: Ethical principles for medical 
research involving human subjects. 2002. Journal of postgraduate medicine. [Online] 
July-September, 48 (3): 206–208. Available: http://www.wma.net/en/30publications/ 
10policies/b3/17c.pdf [2013, October 2]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Central University of Technology, Free State
 72 
  | APPENDICES 
 
Appendix A: Standard operating protocol 
 
Dialysis unit nursing staff, technologists and application specialists were briefed 
about the study in advance by the primary investigator (PI).  
 
Patients’ blood pressure (BP) was recorded using standardised electronic online BP 
monitors as fitted onto haemodialysis machines in accordance to the guidelines set 
by the South African Hypertension Society. 
 
On the study day, the nursing staff, the application specialists and the PI sequentially 
visited the patients and performed the tasks set out below: 
 
Pre-dialysis 
Nursing staff  
 
- Take the patient’s weight and height. 
- Record BP and pulse rate. 
 
PI 
 
- Reviews the patient’s prescription and performs whole body bio-impedance 
measurement. 
- Records dialysis modality, dialysate calcium concentration, intradialytic weight 
gain, body mass index, erythropoietin-stimulating agent dose and route of 
administration, antihypertensives (type and dosage) and haemodialysis 
modality. 
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Dialysis 
Nursing staff 
 
- Record the patient’s BP and pulse rate using electronic online BP monitor 
hourly for four hours. 
- Document standard dialysis hourly observations for duration of dialysis. 
- Record time-averaged sodium towards the end of the dialysis session. 
 
Post-dialysis 
Nursing staff 
 
- Record the patient’s weight, BP and pulse rate 30 minutes after end of 
dialysis. 
 
PI 
 
- Performs whole body bio-impedance measurement. 
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Appendix B: Example of data collection sheet 
Date Patient ID nr Unit Age  Sex Race  Group 
       
 
Nr of AHPT Timing of AHPT ESA dosage Route of 
ESA admin 
    
 
Weight (kg) Height (m) BMI (kg/m²) BCM (OH in L) 
Dry Pre-HD Post-HD     Pre-HD Post-HD 
       
 
BCM (% ECW) Time avg Na (mmol/L) Dialysate Ca (mmol/L) HD/HDF 
Pre-HD Post-HD     
     
 
BP pre-HD (mmHg)  Hourly HD observations 
Sys Dia Sys Dia UF rate (ml/hr) Total UF (ml) 
      
 
Session length (hrs) Sessions per week 
  
Investigator’s name 
Signature 
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Appendix C: Ethics approval 
 
 
Approval Notice 
New Application 
 
 
03- Dec- 2012 
SEBASTIAN, Sajith 
Dear Dr Sajith SEBASTIAN, 
The New Application received on 18-Oct-2012, was reviewed by Health Research 
Ethics Committee 1 via Committee Review procedures on 28-Nov-2012 and has 
been approved.  
 
Please note the following information about your approved research protocol: 
Protocol Approval Period: 28-Nov-2012 - 28-Nov-2013 
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Present Committee Members: 
Kinnear, Craig CJ 
Seedat, Soraya S 
Mukosi, M 
Theunissen, Marie ME 
Kearns, E 
Meintjes, WAJ Jack 
Mohammed, Nazli 
Weber, Franklin CFS 
Nel, Etienne EDLR 
Sprenkels, Marie- Louise MHE 
Rohland, Elvira EL 
Theron, Gerhardus GB 
Els, Petrus PJJS 
De Roubaix, Malcolm JAM 
Hendricks, Melany ML 
Welzel, Tyson B 
Barsdorf, Nicola 
 
Please remember to use your protocol number (S12/10/264) on any documents or 
correspondence with the HREC concerning your research protocol. 
Please note that the HREC has the prerogative and authority to ask further 
questions, seek additional information, require further modifications, or monitor the 
conduct of your research and the consent process. 
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After Ethical Review: 
Please note a template of the progress report is obtainable on www.sun.ac.za/rds 
and should be submitted to the Committee before the year has expired. 
The Committee will then consider the continuation of the project for a further year (if 
necessary). Annually a number of projects may be selected randomly for an external 
audit. 
Translation of the consent document to the language applicable to the study 
participants should be submitted. 
Federal Wide Assurance Number: 00001372 
Institutional Review Board (IRB) Number: IRB0005239 
The Health Research Ethics Committee complies with the SA National Health Act 
No.61 2003 as it pertains to health research and the United States Code of  
Federal Regulations Title 45 Part 46. This committee abides by the ethical norms 
and principles for research, established by the Declaration of Helsinki, the South 
African Medical Research Council Guidelines as well as the Guidelines for Ethical 
Research: Principles Structures and Processes 2004 (Department of Health). 
Provincial and City of Cape Town Approval 
Please note that for research at a primary or secondary healthcare facility permission 
must still be obtained from the relevant authorities (Western Cape Department of 
Health and/or City Health) to conduct the research as stated in the protocol. Contact 
persons are Ms Claudette Abrahams at Western Cape Department of Health 
(healthres@pgwc.gov.za Tel: +27 21 483 9907) and Dr Helene Visser at City Health 
(Helene.Visser@capetown.gov.za Tel: +27 21 400 3981).  
Research that will be conducted at any tertiary academic institution requires approval 
from the relevant hospital manager. Ethics approval is required BEFORE approval 
can be obtained from these health authorities. 
Ethics Refernce #: S12/10/264 
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Title:  A cross-sectional study on Intradialytic Hypertension at Four Haemodialysis 
Units in the Western Cape 
We wish you the best as you conduct your research. 
For standard HREC forms and documents please visit: www.sun.ac.za/rds 
If you have any questions or need further assistance, please contact the HREC 
office at 0219389657. 
Sincerely, 
Franklin Weber 
HREC Coordinator 
Health Research Ethics Committee 1 
 
Included Documents: 
Protocol 
Appendix 
Synopsis 
Declaration 
CVs 
Letter 
Checklist 
Consent 
Application 
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Investigator Responsibilities 
Protection of Human Research Participants 
Some of the responsibilities investigators have when conducting research involving 
human participants are listed below: 
1. Conducting the Research. You are responsible for making sure that the 
research is conducted according to the HREC approved research protocol. 
You are also responsible for the actions of all your co- investigators and 
research staff involved with this research. 
2. Participant Enrolment. You may not recruit or enrol participants prior to the 
HREC approval date or after the expiration date of HREC approval. All 
recruitment materials for any form of media must be approved by the HREC 
prior to their use. If you need to recruit more participants than was noted in 
your HREC approval letter, you must submit an amendment requesting an 
increase in the number of participants. 
3. Informed Consent .You are responsible for obtaining and documenting 
effective informed consent using only the HREC- approved consent 
documents, and for ensuring that no human participants are involved in 
research prior to obtaining their informed consent. Please give all participants 
copies of the signed informed consent documents. Keep the originals in your 
secured research files for at least fifteen (15) years. 
4. Continuing Review. The HREC must review and approve all HREC- approved 
research protocols at intervals appropriate to the degree of risk but not less 
than once per year. There is no grace period. Prior to the date on which the 
HREC approval of the research expires, it is your responsibility to submit the 
continuing review report in a timely fashion to ensure a lapse in HREC 
approval does not occur. If HREC approval of your research lapses, you must 
stop new participant enrolment, and contact the HREC office immediately. 
5. Amendments and Changes. If you wish to amend or change any aspect of 
your research (such as research design, interventions or procedures, number 
of participants, participant population, informed consent document, 
instruments, surveys or recruiting material), you must submit the amendment 
to the HREC for review using the current Amendment Form.  
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You may not initiate any amendments or changes to your research without 
first obtaining written HREC review and approval. The only exception is when 
it is necessary to eliminate apparent immediate hazards to participants and 
the HREC should be immediately informed of this necessity. 
6. Adverse or Unanticipated Events. Any serious adverse events, participant 
complaints, and all unanticipated problems that involve risks to participants or 
others, as well as any research related injuries, occurring at this institution or 
at other performance sites must be reported to the HREC within five (5) days 
of discovery of the incident. You must also report any instances of serious or 
continuing problems, or non- compliance with the HRECs requirements for 
protecting human research participants.  
The only exception to this policy is that the death of a research participant 
must be reported in accordance with the Stellenbosch University Health 
Research Ethics Committee Standard Operating  Procedures 
www.sun025.sun.ac.za/portal/page/portal/HealthSciences/English/Centres% 
20and%20Institutions/ResearchDevelopmentSupport/Ethics/Application 
package. All reportable events should be submitted to the HREC using the 
Serious Adverse Event Report Form. 
7. Research Record Keeping. You must keep the following research related 
records, at a minimum, in a secure location for a minimum of fifteen years: the 
HREC approved research protocol and all amendments; all informed consent 
documents; recruiting materials; continuing review reports; adverse or 
unanticipated events; and all correspondence from the HREC. 
8. Reports to the MCC and Sponsor. When you submit the required annual 
report to the MCC or you submit required reports to your sponsor, you must 
provide a copy of that report to the HREC. You may submit the report at the 
time of continuing HREC review. 
9. Provision of Emergency Medical Care. When a physician provides emergency 
medical care to a participant without prior HREC review and approval, to the 
extent permitted by law, such activities will not be recognised as research nor 
will the data obtained by any such activities should it be used in support of 
research. 
© Central University of Technology, Free State
 81 
10. Final reports. When you have completed (no further participant enrolment, 
interactions, interventions or data analysis) or stopped work on your research, 
you must submit a Final Report to the HREC. 
11. On- Site Evaluations, MCC Inspections, or Audits. If you are notified that your 
research will be reviewed or audited by the MCC, the sponsor, any other 
external agency or any internal group, you must inform the HREC immediately 
of the impending audit/evaluation. 
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Appendix D: ClinicalTrials.gov registration   
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Appendix E: World Congress of Nephrology 2015, abstract submission. 
 
Thank you very much for using the ISN World Congress of Nephrology 2015 abstract submission 
system. Your abstract has been successfully submitted to our database. Your abstract number 
is WCN15-0447 Please keep in mind that NO MORE CHANGES ARE POSSIBLE. In case you have 
further questions or enquiries please contact sstrachova@theisn.org. Please find an overview of your 
saved abstract below: 
Session type Dialysis and transplantation 
Topic Haemodialysis 
Consider for a Young Nephrologists 
Award 
Best abstr. in clinical science-developing country 
Presentation preference Poster Presentation 
Abstract title INTRADIALYTIC HYPERTENSION IN CHRONIC  
HAEMODIALYSIS PATIENTS IN THE WESTERN CAPE,  
SOUTH AFRICA 
S. Sebastian 1.  C. Filmalter 2. M.Y. Chothia1. 
1Tygerberg Hospital, Cape Town, South Africa. 2  Central University of Technology, Health Sciences,  
Bloemfontein, South Africa. 
Introduction 
Intradialytic hypertension (IDH), the paradoxical rise in blood pressure (BP) during haemodialysis,  
increases morbidity and mortality. The reported prevalence is 5-15%. The prevalence in South Africa is 
 unknown.  It is suggested that IDH may be due to subclinical fluid overload. We sought to determine  
the prevalence of IDH in our setting and studied its association with potential risk factors. 
Methods 
A cross-sectional study was conducted at four haemodialysis units in the Western Cape, South Africa. 
 IDH cases were defined as an intradialytic rise  >10mmHg in systolic BP in 4 of 6 consecutive dialysis 
 sessions.  Data were collected on demographics, fluid status using whole body bio-impedance, the 
 haemodialysis procedure and medication. 
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Results 
The prevalence of IDH was 28.4% (n=190). There was a trend toward 'overhydration' in the IDH group  
(2.6 L (95% CI 1.7- 3.4) vs. 1.8 L (95% CI 1.4-2.1); p=0.06) as measured by bio-impedance but no  
difference in mean ultrafiltration volume (2.4 L vs. 2.6 L; p=0.30). Mean age was similar  
(57.1 vs. 55.1 years; p=0.42), as was gender (males 53.7% vs. 59.5%, p=0.40), time-averaged  
sodium concentration (138.4 mM vs. 138.3 mM; p=0.72), dialysate calcium concentration  
(1.34 mM vs. 1.36 mM; p=0.46), weekly erythropoietin stimulating agent dose (6896 IU vs. 6352IU;  
p=0.38) in the IDH versus control groups respectively. A trend towards greater use of antihypertensive  
drugs was noted in the IDH group (2.5 drugs (95% CI 2.15-2.87) vs. 2.1 (95% CI 1.82-2.3); p=0.05).  
More participants in the IDH group received calcium channel blockers (54 vs. 36, p=0.03).  
There was no difference in the use of other antihypertensives. 
Conclusions 
The prevalence of IDH in our treatment centres is high. Subclinical fluid overload may contribute to IDH. 
The use of whole body bio-impedence identifies patients who may benefit from additional ultrafiltration. 
 
Keywords intradialytic hypertension 
haemodialysis 
whole body bio-impedance 
Corporate sponsored research or other substantive relationships: 
Consultation fee from Fresenius Medical Care. 
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